P53779 (MK10_HUMAN) Homo sapiens (Human)

Mitogen-activated protein kinase 10 UniProtKBInterProInteractive Modelling

464 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3); 9 identical sequences: Pan troglodytes: A0A2J8L2H3; Macaca mulatta: A0A1D5QMC7, A0A8J8YAK3; Macaca fascicularis: A0A2K5TUM6; Sapajus apella: A0A6J3ENL5; Fukomys damarensis: A0A091ER56; Saimiri boliviensis boliviensis: A0A2K6U2B1; Carlito syrichta: A0A1U7T522; Orycteropus afer afer: A0A8B7AHP2

Available Structures

61 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal Structure of JNK3 in Complex with JIP1 Peptide Heteromer
Q9UQF2;
45-400
100.0
Crystal Structure of JNK3 in Complex with SAB Peptide Heteromer
O60239;
45-400
100.0
Design and Synthesis of a Novel, Orally Efficacious Tri-substituted Thiophene Based JNK Inhibitor Heteromer
Q9UQF2;
46-401
100.0932;
Crystal Structure of JNK3 in Complex with ATF2 Peptide Heteromer
P15336;
45-400
100.0
Design and Synthesis of Disubstituted Thiophene and Thiazole Based Inhibitors of JNK for the Treatm… Heteromer
Q9UQF2;
46-400
100.0SYY;
Crystal structure of JNK3 in complex with light-activated covalent inhibitor MR-II-249 with both no…monomer44-402
100.00EI;EDO;
Crystal structure of JNK3 in complex with FMU-001-367 (compound 1)monomer45-401
100.00G3; 20×EDO;MES;
The Crystal Structure of JNK3 from Biortus.monomer44-400
100.0ANP;MG;
Crystal structure of JNK3 with indazole inhibitor, SR-3737monomer45-401
100.0JK2;EDO;
Crystal structure of human JNK3 in complex with a benzenesulfonamide inhibitor.monomer44-400
100.03EL;
Discovery of potent and selective covalent inhibitors of JNKmonomer45-401
100.0CQQ;
Discovery of potent and selective covalent inhibitors of JNKmonomer45-401
100.00F0;
Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Se…monomer45-400
100.0X3S;
Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopy…monomer45-400
100.03NL;
Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Se…monomer45-400
100.0X3V;
JNK2/3 in complex with N-(2-methylpyridin-4-yl)-3-{4-[(phenylcarbamoyl)amino]-1H-pyrazol-1-yl}benza…monomer45-400
100.03HJ;
The crystal structure of inhibitor-bound JNK3monomer45-400
100.01RQ;
Crystal Structure of human JNK3 complexed with N-(3-methyl-4-(3-(2-(methylamino)pyrimidin-4-yl)pyri…monomer46-401
100.0BZ9;
Crystal Structure of human JNK3 complexed with an isoquinolone inhibitormonomer45-400
100.046C;GOL;
JNK2/3 in complex with 3-(4-{[(2-chlorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-…monomer45-400
100.03H8;
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitorsmonomer45-400
100.04F2;
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) inhibitorsmonomer45-400
100.0519;
Thiophenyl-Pyrazolourea Derivatives as Potent, Brian Penetrant, Orally Bioavailable, and Isoform-Se…monomer45-400
100.0X3Y;
THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITORmonomer45-400
100.0ANP;880;UNX;
N-Aromatic-Substituted Indazole Derivatives as Brain Penetrant and Orally Bioavailable JNK3 Inhibit…monomer45-400
100.086C;
The crystal structure of AMP-bound JNK3monomer45-400
100.0AMP;
Crystal structure of JNK3 in complex with an imidazole-pyrimidine inhibitormonomer45-400
100.0984;
Crystal structure of JNK3 with amino-pyrazole inhibitor, SR-3451monomer45-400
99.67JK1;EDO;
THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNPmonomer45-400
100.0MG;ANP;
JNK2/3 in complex with 3-(4-{[(4-methylphenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-…monomer45-400
100.03HQ;
c-Jun N-terminal Kinase 3 with 3,5-Disubstituted Quinoline inhibitormonomer46-401
100.0255; 17×UNX;TFA;EDO;
Crystal structure of apo and AMP-bound JNK3monomer45-400
100.0
JNK3 bound to aminopyrimidine inhibitor, SR-3562monomer46-401
100.0FMY;
Synthesis and SAR of Aminopyrimidines as Novel c-Jun N-Terminal Kinase (JNK) Inhibitorsmonomer45-400
100.0J07;
Crystal structure of JNK3 in complex with a fragment moleculemonomer45-400
100.0J6F;
The structure of JNK3 in complex with a dihydroanthrapyrazole inhibitormonomer45-400
100.0537;
JNK2/3 in complex with 3-(4-{[(4-fluorophenyl)carbamoyl]amino}-1H-pyrazol-1-yl)-N-(2-methylpyridin-…monomer45-400
100.03HN;
The crystal structure of JNK3 in complex with a phenantroline inhibitormonomer45-400
100.0CL;9HP;
Inhibitor complex of JNK3monomer45-400
100.0JNK;
JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-phenylindolin…monomer45-400
100.0J88;
Design, synthesis, biological evaluation, and X-ray crystallography of diarylpyrazole derivatives p…monomer45-400
100.0WNK;
IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine bindingmonomer45-400
100.0JNF;
IRAK-4 Inhibitors (Part II)- A structure based assessment of imidazo[1,2 a]pyridine bindingmonomer45-400
100.0JNO;
Highly Selective c-Jun N-Terminal Kinase (JNK) 2 and 3 Inhibitors with In Vitro CNS-like Pharmacoki…monomer46-400
100.0589;
Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitormonomer46-400
100.0BME;CL;BGE;EDO;C15;
Crystal structure of JNK3 in complex with AMP-PCPmonomer46-400
100.0MG;NA;BME;ACP;C15;PEG;
JNK3 (Mitogen-activated protein kinase 10) in Complex with Compound 23 bearing a C(sp3)F2Br moietymonomer46-400
100.0SWM;EDO;GOL;BME;PEG;C15;
inhibitor complex of JNK3monomer46-400
100.0SO4;AIZ;BME;
The MAP kinase JNK3 as target for halogen bondingmonomer46-400
100.03WH;CL;
Crystal Structure of JNK3 complexed with CC-359, a JNK inhibitor for the prevention of ischemia-rep…monomer46-400
100.0JBI;
Crystal structure of human JNK3 complexed with N-{3-cyano-6-[3-(1-piperidinyl)propanoyl]-4,5,6,7-te…monomer46-400
100.0C0M;
Crystal structure of JNK3 in complex with a pyridinylimidazole inhibitormonomer46-400
100.0BME;EDO;B9K;
Crystal Structure of JNK3 complexed with CC-930, an orally active anti-fibrotic JNK inhibitormonomer46-400
100.0KBI;GOL;
JNK3 bound to (Z)-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-4-styrylindolin…monomer46-400
100.0J67;
JNK3 bound to piperazine amide inhibitor, SR2774.monomer46-400
98.72JK3;EDO;
Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic prop…monomer46-400
100.034I;
JNK-3 bound to (Z)-5-fluoro-1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)indoli…monomer46-400
100.0J72;
Crystal structure of JNK3 bound to N-benzyl-4-(4-(3-chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-car…monomer46-400
100.033A;
Crystal structure of human Jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitormonomer46-400
100.0SNB;
Crystal structure of human JNK3 complexed with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-f…monomer46-400
100.0738;
Crystal Structure of human JNK3 complexed with an isoquinolone inhibitormonomer46-400
100.0446;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7yl1.1.Amonomer0.8345-400
J6F;100.00

2 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 27yl1.1.Amonomer0.8345-400
J6F;99.76
Isoform 37yl1.1.Amonomer0.847-362
J6F;100.00